Latest News
In this issue:
- President's Corner
- Researcher Spotlight: Christelle Anaclet, PhD
- Early Success for Proposed New Method of Clearing Toxic Tau
- Is it Alzheimer's? What's Normal, What's Not
- And more!
The FDA has approved a new treatment for “wet” AMD. Known as Vabysmo™, it can extend time between treatments for up to four months.
Early research suggests that modifying cross-talk between the eye’s immune and vascular systems may be a new way to treat AMD.
Extracellular vesicles isolated from the blood of people with Down syndrome-related Alzheimer’s disease have been shown to seed toxic tau species in the brains of normal mice, shedding light on the uptake and transmission of toxic tau.
As retinal cells transition from one state to another, they exhibit molecular changes that correspond to those of liver cells.
A pending Medicare decision could create a “chilling effect” on research.
Tau tangles tend to accumulate in brain cells that also express the Wolframin-1 protein—a discovery that’s been corroborated in human tissue and a mouse model.
BrightFocus-funded researchers crosslink exfoliation syndrome (XFS), a condition that can lead to glaucoma, with common comorbidities and shared risk factors as a way of predicting which patients are at increased risk.
